SCHEMBL21112919

SCHEMBL21112919

O=C([C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O)N1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ AKR1C3 P42330 6/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ LMNA P02545 5/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ NPC1 O15118 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.45
▸ CHIA Q9BZP6 1/20 0.44
▸ ME2 P23368 1/20 0.43
▸ ME1 P48163 1/20 0.43
▸ ME3 Q16798 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21112890 0.87 AKR1C3 (0.51) MEN1KMT2AAKR1C3NPSR1LMNA
SCHEMBL20873300 0.86 TFPI2 (0.54) MEN1KMT2AAKR1C3NPSR1LMNA
SCHEMBL21113012 0.84 L3MBTL1 (0.58) KMT2AAKR1C3LMNAALDH1A1SMN1; SMN2
SCHEMBL21112927 0.81 GAA (0.53) MEN1KMT2AAKR1C3NPSR1LMNA
SCHEMBL21112853 0.76 ALDH1A1 (0.51) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL12508808 0.74 MEN1 (0.62) MEN1KMT2AAKR1C3NPSR1LMNA
SCHEMBL20873280 0.72 PPP5C (0.44) LMNAHTTTSHR
SCHEMBL20873286 0.72 DRD4 (0.45) KMT2AALDH1A1SMN1; SMN2MAPTGFER
SCHEMBL24467419 0.72 ADORA3 (0.40) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL20964570 0.72 MEN1 (0.62) MEN1KMT2AAKR1C3NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885AKR1C3 1463/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885AKR1C3 1463/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885AKR1C3 1463/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MEN1 1610/4885KMT2A 4658/4885AKR1C3 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback